

Pediatric rheumatology: Why rare disease genetics holds the key

Written by The Life Science Feed Editorial Team · Published 26 October 2026 · Edited by Mara Voss

Pediatric rheumatology often presents a diagnostic challenge, with patients enduring prolonged journeys to identify the underlying cause of their conditions. However, insights from rare genetic diseases offer a powerful lens to understand shared disease mechanisms and identify novel therapeutic targets relevant to a broader spectrum of autoimmune and inflammatory disorders.

KEY TAKEAWAYS

- **The Pivot:** Multi-omics integration and whole-exome/whole-genome sequencing are transforming pediatric rheumatology by identifying causal relationships and predictive biomarkers in rare diseases.
- **The Data:** Whole-exome sequencing has demonstrated clinical utility in diagnosing previously undiagnosed conditions, as highlighted by Taft & Varga (2018).
- **The Action:** Consider genomic analysis, such as whole-exome or whole-genome sequencing, for patients with suspected autoimmune or inflammatory conditions, especially those with atypical features or prolonged diagnostic odysseys, to enable more targeted management.

Untapped Potential

Rare diseases, frequently of genetic origin, represent a largely untapped reservoir of information that could revolutionize our understanding of disease mechanisms. In the realm of pediatric rheumatology, where diagnostic odysseys are often the norm, a deeper dive into the genetics of rare conditions could reveal shared pathways and therapeutic targets relevant to a broader spectrum of autoimmune and inflammatory diseases. But is the medical community sufficiently incentivized to pursue these lines of inquiry, given the perceived low return on investment compared to common diseases?

Multi-Omics Integration

The era of single-gene analysis is waning. The future lies in multi-omics approaches – integrating genomics, transcriptomics, proteomics, and metabolomics – to paint a comprehensive picture of disease etiology. This holistic approach allows us to move beyond mere association to identify causal relationships and predictive biomarkers. For instance, identifying a specific transcriptomic signature in a rare form of vasculitis could provide clues to the pathogenesis of more common vasculitides. However, the computational and analytical challenges inherent in handling such large datasets cannot be ignored.

Diagnostic Precision

One of the most immediate benefits of rare disease research is improved diagnostic precision.^{1,2} Whole-exome sequencing and whole-genome sequencing are becoming increasingly accessible, allowing for the identification of

causative mutations in patients with previously undiagnosed conditions.^{2,4} This not only ends the diagnostic odyssey for these patients but also allows for more informed clinical management.^{1,2,4} For example, in cases of suspected systemic lupus erythematosus (SLE) with atypical features, genomic analysis may reveal a monogenic lupus-like disorder, leading to a more targeted treatment approach. Is the cost of these advanced diagnostic tools justified, given the relatively small number of patients who will benefit directly?

Therapeutic Strategies

Rare disease research can also pave the way for novel therapeutic strategies. By identifying the molecular pathways dysregulated in rare diseases, we can develop targeted therapies that address the underlying cause of the disease, not just the symptoms. The success of enzyme replacement therapy in lysosomal storage disorders serves as a prime example. Furthermore, insights gained from rare disease research can inform the development of therapies for more common diseases. For example, understanding the role of interferon signaling in Aicardi-Goutières syndrome, a rare genetic disorder, has led to the development of novel therapies for SLE and other interferonopathies. The long-term efficacy and safety of these targeted therapies must be carefully evaluated.

Collaborative Networks

The rarity of these conditions necessitates the formation of collaborative networks among clinicians, researchers, and patient advocacy groups.¹ These networks facilitate the sharing of data, expertise, and resources, accelerating the pace of discovery and improving patient care.¹ The European Reference Networks (ERNs) for rare diseases serve as a model for such collaborations, bringing together experts from across Europe to address the challenges posed by rare conditions. However, ensuring equitable access to these networks and addressing the potential for data silos remain key challenges. What mechanisms can we put in place to foster truly global collaboration in rare disease research?

The establishment of standardized data collection protocols and interoperable platforms is crucial to overcome these hurdles and maximize the impact of shared insights.¹ Furthermore, addressing ethical considerations surrounding data privacy and informed consent in a global context is paramount to building trust and ensuring sustainable collaboration.

Implementation Challenges and Future Outlook

Despite the immense potential, the widespread integration of rare disease genetics into routine pediatric rheumatology practice faces several significant challenges.⁴ The sheer volume of genetic variants identified through next-generation sequencing necessitates robust bioinformatics pipelines and expert interpretation to distinguish pathogenic mutations from benign polymorphisms. This requires specialized training for clinicians and genetic counselors, a resource that is currently scarce in many healthcare systems. Moreover, the financial burden of comprehensive genetic testing, while decreasing, remains a barrier for many patients and healthcare providers, particularly in resource-limited settings. Strategies for cost-effective implementation, such as targeted gene panels for specific clinical presentations, may offer a pragmatic interim solution while broader accessibility improves.

Looking ahead, the future of pediatric rheumatology will undoubtedly be shaped by advancements in rare disease genetics. The development of artificial intelligence and machine learning algorithms promises to accelerate variant interpretation and identify novel disease associations from vast datasets.³ Furthermore, the burgeoning field of

pharmacogenomics, informed by rare disease insights, holds the potential to personalize treatment strategies, optimizing drug efficacy and minimizing adverse effects. This will move us closer to a precision medicine approach, where each child receives a diagnosis and treatment plan tailored to their unique genetic makeup. However, realizing this vision requires sustained investment in research infrastructure, interdisciplinary training, and robust ethical frameworks to guide the responsible application of these powerful technologies.

CLINICAL IMPLICATIONS

The most striking consequence of embracing rare disease genetics in pediatric rheumatology is the potential to dramatically shorten diagnostic odysseys. For families navigating years of uncertainty, whole-exome and whole-genome sequencing offer a clear path to understanding. This isn't just about a label; it enables precise clinical management and can prevent unnecessary, often harmful, empirical treatments. The cost of these advanced diagnostic tools is increasingly justified by the long-term savings in healthcare resources and, crucially, the improved quality of life for patients. (Taft & Varga, 2018)

For industry, the insights from rare disease research represent a fertile ground for novel therapeutic development. Identifying specific molecular pathways in conditions like Aicardi-Goutières syndrome has already informed therapies for broader interferonopathies, including systemic lupus erythematosus. This "rare-to-common" approach demonstrates that investing in niche areas can yield significant returns for a wider patient population. Companies like Novartis or GlaxoSmithKline, with strong immunology pipelines, should actively seek collaborations within European Reference Networks (ERNs) to leverage this untapped potential. The long-term efficacy and safety of these targeted therapies require rigorous evaluation.

Clinicians must be at the forefront of integrating these advancements. While the computational challenges of multi-omics data are significant, accessible platforms and collaborative networks are emerging to support interpretation. Guideline bodies such as EULAR and national rheumatology societies should prioritize the development of clear pathways for genomic testing in pediatric rheumatology, particularly for atypical presentations or resistant cases. This will ensure equitable access and consistent application of these powerful diagnostic and prognostic tools across Europe.

Ultimately, the patient experience is paramount. Ending the diagnostic odyssey and offering targeted therapies transforms lives. Patient advocacy groups are vital partners in driving this agenda, ensuring that research priorities align with unmet needs. Fostering global collaboration, with standardized data collection and robust ethical frameworks, will accelerate discovery and ensure that no child with a rare rheumatic disease is left behind. (Groft et al., 2020)

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. Laurie S, Steyaert W, de Boer E, et al. Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. *Nat Med*. 2025;31(2):478-489. doi:10.1038/s41591-024-03420-w
2. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. *Nat Rev Genet*. 2018;19(5):253-268. doi:10.1038/nrg.2017.116
3. Zhao W, Wu C, Fan Y, et al. An agentic system for rare disease diagnosis with traceable reasoning. *Nature*. 2026;651(8106):775-784. doi:10.1038/s41586-025-10097-9
4. Wright CF, Campbell P, Eberhardt RY, et al. Genomic Diagnosis of Rare Pediatric Disease in the United Kingdom and Ireland. *N Engl J Med*. 2023;388(17):1559-1571. doi:10.1056/NEJMoa2209046

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com